Drug Topics
MAY 1, 2025
The Inflation Reduction Act's drug price negotiations could lead to reimbursement complexities, potential pharmacy closures, and reduced patient access to medications, particularly specialty drugs.
STAT
MAY 1, 2025
The era of “tranq” may be ending. But tranq, as the powerful veterinary tranquilizer xylazine is known in the illicit drug supply, is being replaced at least in part by a dangerous new sedative: medetomidine. In the past year, the anesthetic has become an increasingly common element in the drug supply, with cities and states including Philadelphia, Pittsburgh, Chicago, and San Francisco reporting cases of medetomidine-involved overdoses.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
APRIL 28, 2025
Antonio Ciaccia, President of 3 Axis Advisors, CEO of 46brooklyn Research, and pharmacy benefits expert, discusses litigious, market-based, and legislative reform for pharmacy benefit managers.
PharmaVoice
APRIL 29, 2025
U.S. health agencies are taking the fight to vaccine and mRNA research, which could have lasting repercussions on medical and scientific advancements.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
APRIL 30, 2025
Research reveals that children face significant long-term health risks, including kidney, gastrointestinal, and cardiovascular issues, after COVID-19 infection.
PhRMA
APRIL 29, 2025
America’s biopharmaceutical companies are committed to revitalizing American manufacturing, and they continue expanding their U.S. footprint. Supporting nearly five million jobs and more than 1,500 facilities across the U.S., we’re making investments that help develop new treatments and cures and contribute to America’s economy.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
APRIL 29, 2025
The explosion of compounded GLP-1 offerings over the past two years is coming to an end, and many patients are left with no good options. Blockbuster obesity and diabetes drugs — such as Wegovy, Ozempic, and Mounjaro — are no longer deemed by regulators to be in shortage, so compounding pharmacies and the telehealth companies they work with must stop offering copies of the treatments.
PharmaVoice
APRIL 30, 2025
A leaked document revealed details about changes that could impact how the agency operates, but recent comments from FDA Commissioner Dr. Marty Makary have muddied the picture.
Hospital Pharmacy Europe
MAY 1, 2025
As the NHS advances, effective clinical leadership in pharmacy is vital to improve the pharmaceutical care of patients. In Scotland, the Scottish Pharmacy Clinical Leadership Fellowship scheme aims to support just that, as Gerry Hughes finds out. The goal of the Scottish Pharmacy Clinical Leadership Fellowship , launched in 2018, is to nurture future pharmacy leaders and advance strategic healthcare goals in Scotland.
PhRMA
MAY 1, 2025
Patients in the U.S. will soon be left with fewer new, affordable and convenient treatments, if Congress fails to fix a harmful provision in the Inflation Reduction Act (IRA) referred to as the “pill penalty.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
APRIL 29, 2025
The word came down at 9 a.m. Pacific on April 14 that they were done. Marcia Stefanick of Stanford and three other leaders of regional centers that for decades have researched women’s health heard from their study’s national leaders that their funding would end with the fiscal year. They all had contracts ready and waiting to be signed to extend their parts of the Women’s Health Initiative, a massive, groundbreaking study that has changed medical practice on hormone therapy,
Pharma Marketing Network
APRIL 28, 2025
Introduction Imagine standing at the edge of a revolution, where every tool you need to succeed is finally within reach. That’s precisely where pharmaceutical marketers find themselves today. Pharma marketing innovation is poised for an unprecedented surge in 2025, driven by new technologies, regulatory shifts, and evolving patient expectations.
PharmaVoice
APRIL 28, 2025
After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.
PhRMA
MAY 1, 2025
The 340B hospital markup program continues to skyrocket every year. Yet there is little to no evidence that this immense growth is benefiting the uninsured and low-income patients that the program was designed to serve. If the money isn’t going to help patients, where is it going?
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
MAY 1, 2025
In the researchers review of data since 1990, they explored the global burden of infertility and the extent in which it is caused by either STIs or maternal sepsis.
STAT
MAY 1, 2025
CVS Health will not sell its Aetna health plans in the Affordable Care Act’s individual marketplaces in 2026, marking the second time in the past decade that Aetna has given up on ACA coverage. CVS expects to lose up to $400 million this year in its ACA plans. The conglomerate set aside $448 million in the first quarter to cover medical claims from ACA members that won’t be covered by insurance premiums.
Pharma Marketing Network
APRIL 29, 2025
Introduction Is traditional advertising losing its edge in the pharmaceutical world? As the industry shifts toward data-driven strategies, the power of audience targeting continues to redefine how brands connect with healthcare professionals (HCPs) and patients. While print ads, radio spots, and mass media campaigns once dominated, the ability to reach the right person at the right time through digital channels has quickly taken the lead.
Hospital Pharmacy Europe
MAY 1, 2025
Consistent adherence to pulmonary hypertension-specific oral therapy significantly improves clinical outcomes, according to a new prospective study evaluating patients with pulmonary arterial hypertension (PAH) and distal chronic thromboembolic pulmonary hypertension (CTEPH). These two conditions are progressive, life-limiting diseases where timely, consistent medication use is critical to stabilise symptoms and prolong survival.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
PhRMA
APRIL 28, 2025
As the United States confronts a resurgence of measles – a disease that was declared eliminated from the United States in 2000 through immunization – it’s a timely reminder of why vaccines remain one of the most powerful tools for preventing dangerous disease, protecting public health and reducing burden on the health care system.
Drug Topics
APRIL 30, 2025
Through digital innovations, transparency, and accessibility, pharmacists can help meet patients where they are at to improve their health outcomes.
STAT
APRIL 29, 2025
Gilead Sciences agreed to pay $202 million to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV medicines, the latest example of a controversial practice that has come back to haunt numerous drugmakers over the years. From 2011 through 2017, Gilead held more than 17,300 speaker programs of which 9,500 were dinners to promote sales of HIV drugs that were supposed to be educational.
PharmaVoice
MAY 1, 2025
Turmoil at the NIH has led to handwringing among researchers and drugmakers who rely on public funding.
Pharma Marketing Network
APRIL 29, 2025
Introduction When was the last time a glossy pharma ad truly resonated with a patient living with chronic illness? In today’s healthcare marketing landscape, trust is the new currencyand real stories matter more than polished commercials. Thats why Influencer Marketing In Pharma is gaining momentum as a critical tool for reaching audiences in a more authentic, impactful way.
PhRMA
APRIL 29, 2025
Today, the Office of the U.S. Trade Representative (USTR) released the 2025 Special 301 Report. PhRMA welcomes USTR’s commitment to defending American innovation against harmful IP and market access practices in trading partners across the globe.
Drug Topics
MAY 1, 2025
Although the market is expected to continue to become more popular, compounding pharmacies will no longer be allowed to manufacture these medications, as shortages have been listed as resolved.
STAT
MAY 1, 2025
Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are wafting across the Pharmalot campus, where the official mascots are foraging for their breakfast and rousing the neighbors. This means we are free to focus on the matters at hand — rummaging through our to-do list and making cups of stimulation. Our choice today is lavender vanilla.
PharmaVoice
APRIL 28, 2025
BMS hopes to broaden the applications for the new schizophrenia drug into areas such as Alzheimer’s disease.
The Checkup by Singlecare
MAY 1, 2025
Prednisone is a type of medication called an oral corticosteroid. Its used to treat inflammation in the body, from conditions like allergies, asthma, arthritis, blood disorders, cancer, autoimmune diseases, and various skin conditions. Prednisone can also be used to calm an overactive immune system. If you are dealing with an itchy, uncomfortable case of poison ivy , you might be wondering if you can use prednisone for poison ivy.
Pharmafile
APRIL 29, 2025
The EU has granted marketing authorisation (MA) for Filspari CSL Vifor and Travere Therapeutics therapy for primary IgA nephropathy (IgAN), a rare kidney disease advancing the ability to administer the therapy to patients globally. Filspari is a dual endothelin angiotensin receptor antagonist(DEARA), a non-immunosuppressive therapy for the treatment of IgAN.
Drug Topics
APRIL 29, 2025
The role of the community pharmacist is beginning to expand into specialty pharmacy spaces to increase access and outcomes for patients.
STAT
APRIL 28, 2025
For the second consecutive year, the pharmaceutical industry saw its reputation slip among patient advocacy groups, largely due to ongoing concerns over pricing issues, according to a new survey. Of more than 2,500 groups queried, 56% reported the industry had an “excellent” or “good” reputation as it goes about the business of developing and providing medicines.
European Pharmaceutical Review
APRIL 29, 2025
The US Pharmacopeia (USP) has launched a selection of resources, including reference materials and standards, to support developers and manufacturers of AAV-based gene therapies. Alongside these resources, USP is publishing the proposed General Chapter <1067> AAV Best Practices for the Manufacture and Quality Control of Recombinant Adeno-Associated Virus (rAAV) Gene Therapy Products.
The Checkup by Singlecare
APRIL 29, 2025
Ozempic (semaglutide) is a glucagon-like peptide-1 receptor agonist, or GLP-1. It was originally approved by the U.S. Food and Drug Administration (FDA) in 2017 to help people with Type 2 diabetes manage their blood sugar levels. The injectable drug’s popularity soared when it was discovered that weight loss was an added bonus. Eventually, the FDA also approved another form of semaglutide , Wegovy , specifically for weight management.
Expert insights. Personalized for you.
501 
Let's personalize your content